Tetracycline News and Research

RSS

Tetracycline is an antibiotic drug used to treat infection.

Study reveals that Hudson River polluted with antibiotic-resistant bacteria

The risk of catching some nasty germ in the Hudson River just started looking nastier. Disease-causing microbes have long been found swimming there, but now researchers have documented antibiotic-resistant strains in specific spots, from the Tappan Zee Bridge to lower Manhattan.

22 Jul 2013

Scientists uncover easy strategies to prevent harmful side-effects of antibiotics responses

A team of scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University has discovered why long-term treatment with many common antibiotics can cause harmful side effects-and they have uncovered two easy strategies that could help prevent these dangerous responses.

4 Jul 2013

Treating bacteria with silver compounds boosts efficacy of old antibiotics

Slipping bacteria some silver could give old antibiotics new life, scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University reported June 19 in Science Translational Medicine.

20 Jun 2013

Montefiore Medical Center professor debunks few beauty claims for pregnant women

Moms of the four million babies born each year in the United States face many claims surrounding their beauty regimens during pregnancy. While some beauty practices should be avoided, there are many solutions for women concerned about whether beauty products could be harmful to their unborn child.

26 Apr 2013

Study reveals humans are passing antibiotic resistance to wildlife in protected areas

A team of Virginia Tech researchers has discovered that humans are passing antibiotic resistance to wildlife, especially in protected areas where numbers of humans are limited.

25 Apr 2013

Arthritis drug reduces dry eye disease

Dry eye disease (DED) is a common condition that causes discomfort, visual disturbance and potentially damaging ocular surface inflammation that greatly impacts a person's quality of life.

19 Apr 2013

Ability to tune gene activity will permit refined research for drug resistance, cancer

Scientists who built a synthetic gene circuit that allowed for the precise tuning of a gene's expression in yeast have now refined this new research tool to work in human cells, according to research published online in Nature Communications.

13 Feb 2013

Gastrointestinal, liver effects common after doxycycline in cats

Doxycycline, an antibiotic derivative of tetracycline, commonly results in adverse gastrointestinal side effects and increased liver enzyme activity in cats, report German researchers.

25 Jan 2013

Paratek receives FDA QIDP designation for omadacycline to treat ABSSSI, CABP

Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic candidate, omadacycline (formerly known as PTK 0796), as a Qualified Infectious Disease Product (QIDP) for both intravenous (IV) and oral formulations in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

3 Jan 2013

UCLA/Pitt scientists uncover P. acnes virus with potential to kill zits

Watch out, acne. Doctors soon may have a new weapon against zits: a harmless virus living on our skin that naturally seeks out and kills the bacteria that cause pimples.

25 Sep 2012

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

13 Sep 2012

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics are medicines used to treat infections or diseases caused by bacteria, such as some respiratory tract infections (including pneumonia and whooping cough), urinary tract infections, skin infections and infected wounds.

6 Sep 2012

Seven antibiotic-resistance genes swapped between human and soil bacteria

Soil bacteria and bacteria that cause human diseases have recently swapped at least seven antibiotic-resistance genes, researchers at Washington University School of Medicine in St. Louis report Aug. 31 in Science.

1 Sep 2012

RNA switches can better equip and regulate viruses for many therapeutic applications

Numerous viruses are used in the service of science today. They serve as gene taxis to transfer therapeutic genes into body cells or as therapeutic viruses targeted to infect and destroy cancer cells. For such applications, the viruses are often equipped with additional genes, such as for immune mediators or for proteins inducing programmed cell death. However, these gene products can harm the body if they are released at the wrong moment or at excessive levels.

22 Aug 2012

FDA approves Levaquin for plague

The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease.

30 Apr 2012

Detrimental effect of tetracycline on male reproductive function, sperm viability of pseudoscorpions

In a paper published today in Nature's open access journal Scientific Reports, researchers at the University of Nevada, Reno report that male pseudoscorpions treated with the antibiotic tetracycline suffer significantly reduced sperm viability and pass this toxic effect on to their untreated sons. They suggest that a similar effect could occur in humans and other species.

30 Apr 2012

Novel tetracyclines with improved potency, efficacy against contemporary P. aeruginosa isolates

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results from studies that demonstrate the improved potency and pharmacokinetics of several of its newest discovery-stage tetracycline analogs.

2 Apr 2012